scholarly journals Initial experience of high-dose helical tomotherapy for medically inoperable esophageal cancer patients

2020 ◽  
Vol 9 (0) ◽  
pp. 15-19
Author(s):  
Etsuko Tate ◽  
Yukihiro Hama ◽  
Manabu Hashimoto
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Helical Tomotherapy ◽  
High Dose ◽  
Initial Experience

scholarly journals EP-1278: CCRT with or without surgery using Helical Tomotherapy or IMRT for esophageal cancer patients

2016 ◽  
Vol 119 ◽  
pp. S601
Author(s):  
P.Y. Hou ◽  
W. Le-Jung ◽  
H. Chen-Hsi ◽  
S. Pei-Wei
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Helical Tomotherapy

Dose accumulation with deformable image registration method using helical tomotherapy images for prostate cancer

2019 ◽  
Vol 19 (1) ◽  
pp. 25-29
Author(s):  
Warit Thongsuk ◽  
Imjai Chitapanarux ◽  
Somsak Wanwilairat ◽  
Wannapha Nobnop
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Image Registration ◽  
Cancer Patients ◽  
Helical Tomotherapy ◽  
Deformable Image Registration ◽  
High Dose ◽  
Registration Method ◽  
Dose Accumulation ◽  
Dose Volume

AbstractPurpose:To evaluate changes of accumulated doses from an initial plan in each fraction by deformable image registration (DIR) with daily megavoltage computed tomography (MVCT) images from helical tomotherapy for prostate cancer patients.Materials and methods:The MVCT images of five prostate cancer patients were acquired by using a helical tomotherapy unit before the daily treatment fraction began. All images data were exported to DIR procedures by MIM software, in which the planned kilovoltage computed tomography (kVCT) images were acting as the source images with the daily MVCT acquired as the target images for registration. The automatic deformed structure was used to access the volume variation and daily dose accumulation to each structure. All dose-volume parameters were compared to the initial planned dose.Results:The actual median doses of the planning target volume (PTV) received 70 Gy and 50.4 Gy were decreased at the end of the treatment with an average 1·0 ± 0·67% and 2·1 ± 1·54%, respectively. As regards organs at risk (OARs), the bladder and rectum dose-volume parameters tended to increase from the initial plan. The high-dose regions of the bladder and rectum, however, were decreased from the initial plan at the end of the treatment.Conclusions:The daily actual dose differs from the initial planned dose. The accumulated dose of target tends to be lower than the initial plan, but tends to be higher than the initial plan for the OARs. Therefore, inter-fractional anatomic changes should be considered by the DIR methods, which would be useful as clinically informative and beneficial for adaptive treatment strategies.

scholarly journals High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

2015 ◽  
pp. 117 ◽  
Author(s):  
Kuaile Zhao ◽  
Chunyu Wang ◽  
Xiaolong Fu ◽  
Xuwei Cai ◽  
Xianghua Wu ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
High Dose

Utility of esophageal stenting for esophageal cancer patients with dysphagia undergoing neoadjuvant therapy.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 105-105 ◽  
Author(s):  
R. E. Brown ◽  
C. R. St. Hill ◽  
M. M. Harkenrider ◽  
S. Ellis ◽  
V. R. Sharma ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Symptom Relief ◽  
High Dose ◽  
Jejunostomy Tube ◽  
Resectable Esophageal ◽  
Prospective Phase ◽  
Esophageal Stenting

105 Background: For esophageal cancer patients with dysphagia, symptom relief and maintenance of nutrition remain significant barriers to completion of neoadjuvant therapy (NAT). We hypothesized that esophageal stenting would allow for successful delivery of planned NAT, with improvement in quality of life (QOL) and maintenance of nutrition. Methods: A multi-institution prospective phase II clinical trial examined esophageal cancer patients with dysphagia undergoing NAT. All had a self-expanding polymer esophageal stent (ES) placed at initiation of NAT. Individual chemotherapy and RT regimens were determined via multidisciplinary collaboration. Results: 32 patients were enrolled with dysphagia and potentially resectable esophageal cancers. All had ES placement prior to NAT. Two patients had stent migrations that required replacement. There were no ulcerations or perforations. Significant QOL improvements were noted within a week after ES placement, which persisted throughout NAT. NAT with chemo + RT was planned in 17 patients, of which 12 (71%) received planned dosing. NAT with chemotherapy alone was planned in 15 patients, of which 10 (67%) received planned dosing. Chemotherapy was most commonly 5FU/cisplatin based. 3D conformal RT with high dose photons was used most frequently, with a mean of 97% of the planned RT dose delivered. Among all patients, alterations (n=5, 16%) or cessation (n=5, 16%) of planned NAT regimens were required for treatment-related toxicity or disease progression. One patient required a jejunostomy tube for nutritional maintenance. Conclusions: Esophageal stenting is an effective method of improving QOL and relieving symptoms that allows for successful completion of NAT, with maintenance of performance and nutritional status. [Table: see text]

scholarly journals 92: Radiation Dose to Organs At Risk After High Dose Rate Brachytherapy for Esophageal Cancer Patients

2020 ◽  
Vol 150 ◽  
pp. S41
Author(s):  
Sahar Darvish-Molla ◽  
Emilia Timotin ◽  
Jack Skoczny ◽  
Thomas Farrell ◽  
Ranjan K. Sur
Keyword(s):  
At Risk ◽  
Esophageal Cancer ◽  
Radiation Dose ◽  
Dose Rate ◽  
Cancer Patients ◽  
Organs At Risk ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy

Helical tomotherapy for advanced esophageal cancer improves target conformity and homogeneity: A comparison with fixed-field intensity-modulated radiotherapy

2015 ◽  
Vol 11 (3) ◽  
pp. 3146-3155
Author(s):  
Luhua Wang
Keyword(s):  
Esophageal Cancer ◽  
Field Intensity ◽  
Helical Tomotherapy ◽  
Intensity Modulated Radiotherapy ◽  
Matched Pair ◽  
Conformity Index ◽  
Target Coverage ◽  
Advanced Esophageal Cancer ◽  
Fixed Field ◽  
Intensity Modulated

Purpose: To evaluate the usefulness of helical tomotherapy (HT) in the treatment of advanced esophageal cancer (EC) and compare target homogeneity, conformity and normal tissue doses between HT and fixed-field intensity-modulated radiotherapy (ff-IMRT).Methods: In all, 23 patients with cT3-4N0-1M0-1a thoracic EC (upper esophagus, 9 patients; middle esophagus, 6; distal esophagus, 6 and esophagogastric junction, 2) who were treated with ff-IMRT (60 Gy in 30 fractions) were re-planned for HT and ff-IMRT with the same clinical require­ments. Comparisons were performed using the Wilcoxon matched-pair signed-rank test.Results: Compared with ff-IMRT, HT significantly reduced the homogeneity index for thoracic, upper, middle and distal ECs by 38%, 31%, 36% and 33%, respectively (P < 0.05). The conformity index was increased by HT for thoracic, upper and middle ECs by 9%, 9% and 18%, respectively (P < 0.05). Target coverage was improved by 1% with HT (P < 0.05). The mean lung dose was significantly reduced by HT for thoracic and upper ECs (P < 0.05). The V20 (volume receiving at least 20 Gy) and higher dose volumes of the lungs were decreased by HT in all cases, but the differences were significant for thoracic, upper and distal ECs (P < 0.05), with reductions of 2.1%, 3.1% and 2.2%, respectively. HT resulted in a larger lung V5 for thoracic, upper, middle and distal ECs, with increases of 3.5%, 1.5%, 7.2% and 3.2%, respectively. Heart sparing was significantly better with HT than with ff-IMRT in terms of the V30 and V40 for thoracic, upper, middle and distal ECs (P < 0.05).Conclusions: Compared to ff-IMRT, HT provides superior target coverage, conformity and homogeneity, with reduced the volume of high doses to the lungs and heart for advanced EC. HT may be a treatment option for advanced EC, especially upper EC.

Self-expandable Metallic Stent Insertion for Nonresectable Esophageal Cancer Patients.

2001 ◽  
Vol 52 (2) ◽  
pp. 75-81
Author(s):  
Hideo Shimada ◽  
Osamu Chino ◽  
Takayuki Nishi ◽  
Hikaru Tanaka ◽  
Yoshifumi Kise ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Stent Insertion ◽  
Metallic Stent ◽  
Expandable Metallic Stent
Sign in / Sign up

Export Citation Format

Share Document